Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Yes for specific peptides
See our insurance coverage guide for insurer-specific details
However, because GLP-1 treatments typically begin at a low titration dose to allow the body to adjust and minimize side effects, the appetite suppression may feel mild during the first week
Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products
Counterstaining was performed with Mayers hematoxylin
Ultimately, there is a pressing need to understand whether the beneficial indirect effects of GLP-1RA medications on pancreatic diseases, including PDAC (e.g., weight loss), are negated by direct effects on the pancreas
